Entia Biosciences is selling at 1.0E-4 as of the 18th of March 2025; that is No Change since the beginning of the trading day. The stock's open price was 1.0E-4. Entia Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. The company has 33.66 M outstanding shares. More on Entia Biosciences
Entia Biosciences [ERGO] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 235.63 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Entia Biosciences's market, we take the total number of its shares issued and multiply it by Entia Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Entia Biosciences conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 33.66 M outstanding shares.
Entia Biosciences currently holds about 76.05 K in cash with (715.1 K) of positive cash flow from operations.
Check Entia Biosciences Probability Of Bankruptcy
Our tools can tell you how much better you can do entering a position in Entia Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run CEOs Directory Now
CEOs Directory
Screen CEOs from public companies around the world
Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.